{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:30:16Z","timestamp":1786480216792,"version":"build-2736575974"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.34067\/kid.0001072019","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T16:49:26Z","timestamp":1585241366000},"page":"166-168","source":"Crossref","is-referenced-by-count":18,"title":["Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor\u2013Associated Acute Kidney Injury: Commentary"],"prefix":"10.34067","volume":"1","author":[{"given":"Mark A.","family":"Perazella","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut; and"},{"name":"Section of Nephrology, Veterans Affairs Connecticut Medical Center, West Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2217\/fon-2017-0585","article-title":"Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer","volume":"14","author":"Anari","year":"2018","journal-title":"Future Oncol"},{"key":"B2-20230821","first-page":"4105","article-title":"Present and future of cancer immunotherapy: A tumor microenvironmental perspective","volume":"16","author":"Yu","year":"2018","journal-title":"Oncol Lett"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.cllc.2016.09.010","article-title":"Association of PD-1, PD-L1, and CTLA-4 gene expression and clinicopathologic characteristics in patients with non-small-cell lung cancer","volume":"18","author":"Lafuente-Sanchis","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: Past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: What do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41581-018-0035-1","article-title":"Cardiorenal complications of immune checkpoint inhibitors","volume":"14","author":"Sury","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","article-title":"Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1","volume":"4","author":"Cassol","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrneph.2010.71","article-title":"Drug-induced acute interstitial nephritis","volume":"6","author":"Perazella","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2215\/CJN.07630717","article-title":"Drug-induced acute interstitial nephritis","volume":"12","author":"Moledina","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor\u2013associated AKI: A multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001072019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:58:02Z","timestamp":1786478282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001072019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0001072019","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}